Commenting on the deal, Alberto Giovanni Aleotti, Vice Chairman of Menarini Group said: "We are delighted and honored to further strengthen our long-term partnership with Gilead to help address the needs of angina patients in these new territories, in particular the Asia Pacific region."
Alberto Giovanni Aleotti, a member of Menarini's board of directors, adds, "we are eager to start our collaboration with OBT, an oncology company with a proven track record of generating innovative antibody-based cancer drug candidates that are designed to address high unmet medical needs.
" Research in new treatments for gout has been absent for nearly forty years, making it an orphan disease in some respects" declared Dr. Alberto Aleotti, Chairman and Chief Executive Officer of the Menarini Group " We are therefore extremely proud that Ipsen has chosen Menarini as the ideal partner to substantially contribute to European patients' health with an innovative drug in this therapeutic area".
Alberto Giovanni Aleotti, member of the Board of A. Menarini, commented, "Working with OBT is a fantastic opportunity, and Menarini believe that alliances like this should be embraced on a wider scale to ensure that novel and targeted therapies are brought to market efficiently, with the ultimate aim always of providing the best treatment options possible to healthcare professionals and their patients."
Alberto Giovanni Aleotti, Member of the Board of Menarini Group stated, "Priligy® is an innovative drug and the only product that has received regulatory approval specifically for the treatment of premature ejaculation.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.